Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis

Next Previous
X
Search
Trial Profile

A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary)
  • Indications Cardiovascular disorders; Plaque psoriasis
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms VIP-A

    • Most Recent Events

    • 12 Sep 2022 Primary endpoint has not been met. (Change in total vascular inflammation of the aorta as measured by [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) / computed tomography (CT) (FDG-PET/CT) between baseline and week 16.)
    • 12 Sep 2022 Results published in the JAMA Dermatology
    • 13 Jan 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top